Liraglutide Injection, Solution
Product Images NDC 69097-910

Product Visual Gallery

This gallery contains 43 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 69097-910). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (189c8df8 3ed2 4b54 Adc4 D08b6a4260fb 186 1)

The image shows a white and orange carton for liraglutide injection, solution with a strength of 6 mg/mL. The packaging indicates that it is intended for subcutaneous use. The labeler is Cipla USA Inc., and the product includes a single carton containing one 3 mL prefilled pen injector. The brand name is not prominently displayed, but the generic name liraglutide is clear.*

FDA Label Image

Image (26134562 79de 4b8b 9c8b 6d6c5ec72206 02)

Chemical structure diagram representing the sequence of amino acids and inclusion of a C-16 fatty acid (palmitoyl) chain, illustrating the molecular composition of liraglutide.*

FDA Label Image

Figure 2 (26134562 79de 4b8b 9c8b 6d6c5ec72206 03)

Two cumulative frequency graphs showing the percentage change in body weight for liraglutide injection versus placebo. The graphs illustrate cumulative frequency (%) on the vertical axis and change in body weight (%) on the horizontal axis, comparing liraglutide injection and placebo responses using multiple imputations (MI) in intention-to-treat (ITT) analysis.*

FDA Label Image

Image (26134562 79de 4b8b 9c8b 6d6c5ec72206 04)

Two line graphs showing the percentage change in body weight over weeks, comparing liraglutide injection to placebo. The left graph covers approximately 36 weeks, while the right graph extends to about 56 weeks, both noting differences in weight reduction favoring liraglutide injection. Patient counts at various weeks and study completion notes are included below the graphs.*

FDA Label Image

Image (26134562 79de 4b8b 9c8b 6d6c5ec72206 05)

A line graph comparing percent body weight change over weeks between liraglutide injection and placebo groups. The x-axis shows time in weeks, and the y-axis shows percent change in body weight. The liraglutide group shows a greater decrease in body weight compared to placebo.*

FDA Label Image

Image (26134562 79de 4b8b 9c8b 6d6c5ec72206 06)

Line graph shows change from baseline in BMI SDS (Body Mass Index Standard Deviation Score) over time in weeks for liraglutide injection versus placebo groups. BMI SDS decreases over time with liraglutide while remaining near baseline with placebo. Error bars represent standard error of the mean.*

FDA Label Image

Example Diagram (26134562 79de 4b8b 9c8b 6d6c5ec72206 07)

Illustration of a liraglutide injection pen and needle showing labeled parts including the pen cap, pen scale, pen window, dose counter, dose pointer, dose selector, and dose button. Additional needle components are labeled: outer needle cap, inner needle cap, needle, and paper tab. The pen label indicates liraglutide injection 18 mg/mL (1.8 mg).*

FDA Label Image

Carton Label (3 pack)

Liraglutide Injection 18 mg/3 mL (6 mg/mL) subcutaneous injection solution, packaged in a box containing 3 x 3 mL prefilled pens. The labeler is Cipla USA Inc. The packaging features instructions and warnings, manufacturer and distributor details, and images of the prefilled pen and its parts. The label advises refrigerating but not freezing, single-patient use, and use with specific needles.*

FDA Label Image

Carton Label (5 pack)

Liraglutide Injection 18 mg/3 mL (6 mg/mL) in prefilled pens, packaged 5 pens per box. It is a subcutaneous injectable solution with a blue and white carton labeled Cipla USA, Inc. The label includes usage directions, storage instructions such as refrigeration and protecting from light, and recommends use with NovoFine or BD Ultra-Fine disposable needles. Manufacturer is Orbicular Pharmaceutical Technologies Private Limited, India.*

FDA Label Image

Pen Label (26134562 79de 4b8b 9c8b 6d6c5ec72206 10)

Label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) subcutaneous injection solution, distributed by Cipla USA Inc. The label includes usage instructions, storage conditions, and manufacturer information. It states the product is for single patient use and contains a barcode and QR code with unvarnished area for batch and expiration details.*

FDA Label Image

520ddc77-af62-4274-8f7e-e1ba260b4e36-142-36 (520ddc77 1f62 4274 8f7e E1ba260b4e36 142 36)

An instructional illustration showing a hand removing a protective cap from the tip of a liraglutide injection pen. The pen is labeled with dosage markings and is intended for subcutaneous injection.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 10)

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 11)

An instructional illustration showing how to perform a flow check on a liraglutide injection pen device. The image depicts hands holding the pen, with an arrow indicating the rotation to select the flow check symbol. An inset highlights the flow check symbol on the dose selector.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 12)

liraglutide 6 mg/mL injection, solution in a subcutaneous injection pen, labeled with Cipla USA Inc. The pen contains 3 mL of solution, designed for subcutaneous administration. The label includes clear black text on a white background and features measurement markings on the pen's dosing window.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 13)

Liraglutide injection, solution 6 mg/mL by Cipla USA Inc. The label shows the vial for subcutaneous use with the product name and strength prominently displayed. The packaging includes information about dosage form and manufacturer.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 14)

An instructional illustration showing a hand holding a liraglutide injection pen. The image includes a close-up inset of the pen's top, emphasizing the step to pull or remove a cap, indicated by an upward arrow, preparing the pen for subcutaneous injection use.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 15)

Packaging label of liraglutide injection solution, 6 mg/mL, from Cipla USA Inc. The label indicates the product name liraglutide, strength 6 mg/mL, and specifies that it is a subcutaneous solution. The label includes a barcode and other regulatory and manufacturing information.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 16)

liraglutide 6 mg/mL injection solution in a visible pharmaceutical vial labeled with the product name, strength, dosage form, and subcutaneous route. The label includes the Cipla USA Inc. name, consistent with FDA-registered human prescription drug packaging. The vial is clear with a yellow cap, showing the medication inside.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 17)

An instructional illustration showing a close-up of a liraglutide injection pen with a dose selector. The image highlights a dose window displaying "0.6 mg" selected, accompanied by an arrow indicating the action to select or adjust the dose. The diagram also includes a depiction of fingers holding the pen for dose adjustment.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 18)

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 19)

An instructional diagram showing a liraglutide injection pen with dose markings at 0.6 mg, 3 mg, and 6 mg levels. The image highlights an example dose selection with approximately 3 mg of liraglutide solution remaining in the pen.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 2)

An instructional diagram showing hands twisting the cap off a pen-like injection device, indicated by an arrow pointing to the right. This visual likely illustrates the initial step for preparing a liraglutide 6 mg/mL subcutaneous injection pen for use.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 20)

The image shows a white carton box for liraglutide injection, solution, 6 mg/mL, labeled for subcutaneous use. The packaging features the brand name liraglutide prominently along with the strength and form. The labeler is Cipla USA Inc., and the box design includes typical pharmaceutical labeling elements such as dosage and route information.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 21)

The image shows a vial label for liraglutide injection, solution at a concentration of 6 mg/mL. The label includes dosage form and route indication as a subcutaneous injection, with the labeler identified as Cipla USA Inc. The vial has a white cap and features black and white print detailing the product information.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 22)

Illustration showing a close-up of a liraglutide injection pen dose counter. The upper part shows a hand pulling a tab or knob with an arrow pointing upward, and the dose counter displaying "0 mg". The lower part shows a dose counter displaying "2.4 mg" with a caption stating "Example Dose counter stopped: 2.4 mg left."*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 23)

An illustration depicting a hand holding a liraglutide injection pen, with a downward arrow indicating the direction to administer the subcutaneous injection.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 24)

An instructional illustration showing a hand holding a liraglutide injection pen, pressing down the injection button to administer a subcutaneous injection. An inset shows the dose window displaying '0 mg', indicating dose selection or completion.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 25)

Illustration showing a hand holding a liraglutide injection pen with instructions to count slowly to six during the subcutaneous injection. The image indicates the proper use timing for liraglutide 6 mg/mL injection solution by Cipla USA Inc.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 26)

Packaging label for liraglutide injection, solution, 6 mg/mL, by Cipla USA Inc. The front panel of the carton displays the proprietary and generic name, strength, dosage form, the route of administration as subcutaneous, and the NDC number 69097-910. The carton is primarily white with purple accents and includes standard regulatory information.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 27)

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 28)

An instructional illustration showing a liraglutide injection pen with a visible dose scale and a needle attached. A large blue arrow points upward, indicating the direction or motion likely related to preparing or administering the subcutaneous injection.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 29)

An instructional illustration showing a hand twisting the needle onto a syringe or pen device, labeled with the word 'Needle' at the top. The image guides the user on attaching the needle to the injection device for subcutaneous administration.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 3)

An instructional illustration showing a hand holding a liraglutide 6 mg/mL subcutaneous injection pen, focusing on the dial or dosage window area of the pen device. The image depicts the method to adjust or view the dose setting before administration.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 30)

An instructional illustration showing the process of applying a medicinal liquid drop onto a circular device with a petal-like indentation. The illustration includes a small container with a nozzle dispensing liquid and an arrow indicating the direction of the drop placement.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 31)

Illustration showing a close-up of hands holding a liraglutide injection pen. The image depicts twisting the pen cap off to prepare the subcutaneous injection solution for use.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 32)

The image shows a box of liraglutide injection, solution for subcutaneous use, with a concentration of 6 mg/mL. The product is labeled as a human prescription drug by Cipla USA Inc. The packaging is primarily white with blue and orange design elements, and includes the Cipla logo.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 33)

The image shows the carton packaging of liraglutide injection, solution, 6 mg/mL by Cipla USA Inc. The rectangular box features purple and white colors with the name 'liraglutide' prominently displayed. The product is identified as a subcutaneous injection with a NDC of 69097-910.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 34)

liraglutide 6 mg/mL injection, solution in a subcutaneous administration, shown in a small vial with a clear label. The label displays the product name liraglutide prominently with concentration 6 mg/mL. Manufactured by Cipla USA Inc. The vial is clear with a grey stopper and appears to be a single-dose container.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 35)

Illustration showing the attachment of a small needle cap or protective cover to a syringe or injection pen used for liraglutide injection, solution 6 mg/mL. Arrows indicate the direction for connecting the needle cap securely before administration.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 36)

The packaging label for liraglutide 6 mg/mL injection, solution for subcutaneous use, manufactured by Cipla USA Inc. The packaging displays the proprietary and generic name, dosage form, strength, and includes storage and handling information. It also features FDA and safety symbols, barcodes, and the product NDC 69097-910.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 4)

An instructional illustration showing hands removing or preparing the needle attached to a liraglutide injection pen. The image highlights the step involving handling the needle cap or cover before injection.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 5)

An instructional illustration showing a hand holding a syringe-style injection device. The thumb is positioned to twist or activate the pen needle cap, indicated by a curved arrow, demonstrating a step in preparing the injection for use.*

FDA Label Image

Image (520ddc77 Af62 4274 8f7e E1ba260b4e36 142 6)

An instructional diagram showing the connection of a syringe needle to the liraglutide injection pen. It depicts a hand attaching the needle to the pen by pressing and twisting, with a blue arrow indicating the direction of attachment. This is part of the subcutaneous injection preparation process.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.